guest ::
| Home > Publications database > Variation of positive predictive values of fecal immunochemical tests by polygenic risk score in a large screening cohort. > print |
| Home > Publications database > Variation of positive predictive values of fecal immunochemical tests by polygenic risk score in a large screening cohort. > print |
| 001 | 178590 | ||
| 005 | 20240229143550.0 | ||
| 024 | 7 | _ | |a 10.14309/ctg.0000000000000458 |2 doi |
| 024 | 7 | _ | |a pmid:35060941 |2 pmid |
| 024 | 7 | _ | |a altmetric:121385210 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00139 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Niedermaier, Tobias |0 P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Variation of positive predictive values of fecal immunochemical tests by polygenic risk score in a large screening cohort. |
| 260 | _ | _ | |a London |c 2022 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1651150675_30565 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:C070#LA:C070#LA:C120# / 2022 Jan 19;13(3):e00458 |
| 520 | _ | _ | |a Prevalence of colorectal neoplasms varies by polygenic risk scores (PRS). We aimed to assess to what extent PRS might be relevant for defining personalized cutoff values for fecal immunochemical tests (FITs) in colorectal cancer (CRC) screening.Among 5,306 participants of screening colonoscopy who provided a stool sample for a quantitative FIT (Ridascreen Hemoglobin or FOB Gold) prior to colonoscopy a PRS was determined, based on the number of risk alleles in 140 , single nucleotide polymorphism. Subjects were classified into low, medium and high genetic risk for colorectal neoplasms according to PRS tertiles. We calculated positive predictive values (PPVs) and numbers needed to scope (NNS) to detect one advanced neoplasm (AN) by risk group, and cutoff variation needed to achieve comparable PPVs across risk groups in the samples tested with Ridascreen (N=1,271) and FOB Gold (N=4,035) independently, using cutoffs yielding 85%, 90% or 95% specificity.Performance of both FITs was very similar within each PRS group. For a given cutoff, PPVs were consistently higher by 11%-15% units in the high-risk PRS group compared to the low-risk group (all P-values <0.05). Correspondingly, numbers needed to scope (NNS) to detect one advanced neoplasm varied from 2 (high PRS, high cutoff) to 5 (low PRS, low cutoff). Conversely, very different FIT cutoffs would be needed to ensure comparable PPVs across PRS groups.PPVs and NNS of FITs varied widely across people with high and low genetic risk score. Further research should evaluate the relevance of these differences for personalized CRC screening.This study was partly funded by grants from the German Research Council (DFG, grant No. BR1704/16-1), the Federal Ministry of Education and Research (BMBF, grant no. 01GL1712), and the German Cancer Aid (No. 70113330). |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 700 | 1 | _ | |a Balavarca, Yesilda |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Gies, Anton |0 P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922 |b 2 |u dkfz |
| 700 | 1 | _ | |a Weigl, Korbinian |0 P:(DE-He78)f4e98340e600f7411886c21c7b778d36 |b 3 |u dkfz |
| 700 | 1 | _ | |a Guo, Feng |0 P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919 |b 4 |u dkfz |
| 700 | 1 | _ | |a Alwers, Elizabeth |0 P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63 |b 5 |u dkfz |
| 700 | 1 | _ | |a Hoffmeister, Michael |0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |b 6 |u dkfz |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 7 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.14309/ctg.0000000000000458 |g Vol. Publish Ahead of Print |0 PERI:(DE-600)2581516-7 |n 3 |p e00458 |t Clinical and translational gastroenterology |v 13 |y 2022 |x 2155-384X |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:178590 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)f4e98340e600f7411886c21c7b778d36 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version) |0 LIC:(DE-HGF)CCBYNCNDNV |2 V:(DE-HGF) |b DOAJ |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-29 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-01-29 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-01-29 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN TRANSL GASTROEN : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2019-08-29T13:10:21Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2019-08-29T13:10:21Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2019-08-29T13:10:21Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-12 |
| 920 | 2 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 2 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
| 920 | 0 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|